CeriBell Inc

CBLL

市值 US$9.6億

SUNNYVALE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared new software for the Ceribell System that makes it easier and faster for clinicians to interpret longitudinal brain activity and make appropriate clinical decisions.1 Brain monitoring with electroencephalography (EEG) can generate hours of complex data that can be difficult to interpret in a timely manner.

CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base.

CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.38 per share a year ago.

CeriBell NASDAQ: CBLL reported second-quarter 2026 revenue growth of 33% as increased utilization at existing hospital accounts and continued customer additions supported results. The company also raised its full-year revenue outlook and outlined plans to commercially launch its delirium-monitoring solution later this year.

SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for two new AI algorithm enhancements integrated directly into its existing cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction.1 These new capabilities expand the clinical utility of the Ceribell Point-of-Care (POC) brain monitoring system, providing neurologists and bedside practitioners with an enhanced toolset for rapid, high-confidence electroencephalogram (EEG) assessment.

Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform

SUNNYVALE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointments of Thomas “Tom” West and Sharon O'Keefe to its Board of Directors.

SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston. The fireside chat will take place on Wednesday, August 12, 2026, at 6:00 a.m. Pacific Daylight Time / 9:00 a.m. Eastern Daylight Time.